GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cantourage Group SE (XTER:HIGH) » Definitions » Capex-to-Revenue

Cantourage Group SE (XTER:HIGH) Capex-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Cantourage Group SE Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Cantourage Group SE's Capital Expenditure for the six months ended in Jun. 2023 was €0.00 Mil. Its Revenue for the six months ended in Jun. 2023 was €0.60 Mil.

Hence, Cantourage Group SE's Capex-to-Revenue for the six months ended in Jun. 2023 was 0.00.


Cantourage Group SE Capex-to-Revenue Historical Data

The historical data trend for Cantourage Group SE's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantourage Group SE Capex-to-Revenue Chart

Cantourage Group SE Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
- - - -

Cantourage Group SE Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23
Capex-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Cantourage Group SE's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cantourage Group SE's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantourage Group SE's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cantourage Group SE's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cantourage Group SE's Capex-to-Revenue falls into.



Cantourage Group SE Capex-to-Revenue Calculation

Cantourage Group SE's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.603
=0.00

Cantourage Group SE's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.599
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantourage Group SE  (XTER:HIGH) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Cantourage Group SE Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cantourage Group SE's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantourage Group SE (XTER:HIGH) Business Description

Comparable Companies
Traded in Other Exchanges
Address
Feurigstrasse 54, Berlin, DEU, 10827
Cantourage Group SE is a medical cannabis company. The company offers products in all relevant market segments: dried flowers, extracts, Dronabinol, and pharma-grade Cannabidiol.
Executives
Patrick Hoffmann Supervisory Board
Dr. Florian Kainzinger Supervisory Board
Dr. / Dr. Florian / Michael Kainzinger / Ruoff Supervisory Board
Dr. / Dr. Florian /michael Kainzinger / Ruoff Supervisory Board
Dr. / Herr Florian / Patrick Holzapfel / Hoffmann Supervisory Board
Dr. Florian Holzapfel Supervisory Board
Dr. Michael Ruoff Supervisory Board

Cantourage Group SE (XTER:HIGH) Headlines